PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9,275.00
Bid: 9,275.00
Ask: 9,285.00
Change: 0.00 (0.00%)
Spread: 10.00 (0.108%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9,275.00
SPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

7 Nov 2014 07:00

RNS Number : 4096W
Spirax-Sarco Engineering PLC
07 November 2014
 



 

News Release

 

Friday 7th November 2014

INTERIM MANAGEMENT STATEMENT

Continued good performance in challenging markets

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2014 to 6th November 2014.

 

Trading

In the four-month period ended 31st October 2014, organic sales growth was 5%. The profile of growth across our four segments has remained largely consistent with the first half. Watson-Marlow has again performed well with growth accelerating since June in emerging markets and North America, and with a continuing good contribution from Bio Pure that was acquired at the start of the year. In our steam specialties business, in Europe, Middle East and Africa ("EMEA") organic growth has continued at the same pace as in the first half year. In Asia Pacific, as expected when we last reported in August, we have started to reduce the high level of order book and expect further progress in reducing this order book over the remainder of this year in line with the traditional pattern in the fourth quarter. Finally in the Americas, sales growth in the four months to October improved due to Latin America.

 

In the four month period ended 31st October 2014, Group operating profit at constant currency was ahead of the comparable period in 2013. For the ten months to October 2014, the Group operating profit margin remained ahead on both a constant currency and reported basis, despite persistent exchange rate headwinds. If current exchange rates prevail for the remainder of the year, we now expect that sales for 2014 will be reduced by 6.3% on translation compared with full-year 2013 average exchange rates. The impact on operating profit continues to be somewhat greater, at an estimated 10% for the year, reflecting the same additional exchange transaction effects previously indicated.

 

Financial position

The Group remains highly cash generative and maintains a strong balance sheet, with the net cash balance increasing from £16 million at 31st December 2013 to £35 million at 31st October 2014, despite the £9 million outflow in respect of the acquisition of Bio Pure in January and the adverse impact of currency movements on translation of cash balances. The interim dividend of 19.5p per share (total cost £15 million) will be paid today. There has been no material change in the financial position of the Group during the period and the principal risks and uncertainties remain as set out on pages 26 and 27 of the 2013 Annual Report.

 

Outlook

Steam is widely used across a diverse range of industries and our markets generally reflect the pace of growth in Industrial Production, which our markets typically lag by a few quarters. The up-tick in global Industrial Production seen since late 2013 has begun to reverse and recent economic indicators point to lower rates of growth in both developed and emerging markets, particularly China. We remain focused on taking actions to out-perform our markets by generating our own growth through the implementation of our strategic growth initiatives and we will continue to focus on costs. Our business is resilient and we remain well placed if economic conditions deteriorate. We have a powerful direct-sales business model, with a wide geographic spread, diverse industrial end markets, a broad customer base and with a large proportion of our revenues deriving from customers' maintenance and operating spend. Our order book remains at a relatively high level, which is supportive of our expectation for sales growth in the remainder of the year and underpins the Board's confidence that we will make further progress in 2014.

 

 

 

Enquiries:

Nick Anderson, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note: References to profit are to adjusted profit that excludes the amortisation and impairment of acquisition-related intangible assets and acquisition and disposal costs, together with the tax effects of these items.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBGUGBGSL
Date   Source Headline
9th Aug 20183:07 pmRNSDirector/PDMR Shareholding
8th Aug 20187:00 amRNSHalf Year Results
31st Jul 201810:22 amRNSHolding(s) in Company
25th Jul 20189:46 amRNSChange of Director Details
20th Jul 201810:00 amRNSExecutive Director Promotion
11th Jun 20184:26 pmRNSHolding(s) in Company
31st May 20188:12 amRNSDirector/PDMR Shareholding
17th May 20189:26 amRNSDirector/PDMR Shareholding
15th May 20184:55 pmRNSResult of AGM
15th May 20187:00 amRNSAGM Statement - Trading Update
25th Apr 20184:27 pmRNSDirector/PDMR Shareholding
6th Apr 20183:32 pmRNSDirector/PDMR Shareholding
4th Apr 20184:17 pmRNSDirector/PDMR Shareholding
29th Mar 20184:24 pmRNSTotal Voting Rights
29th Mar 20184:20 pmRNSDirector/PDMR Shareholding
15th Mar 20187:00 amRNS2017 Preliminary Results
6th Mar 20187:00 amRNSBoard Appointment
14th Feb 20187:00 amRNSBoard Succession Changes
6th Feb 20187:30 amRNSChange of Director Details
20th Dec 20179:07 amRNSChange of Director Details
27th Nov 20174:00 pmRNSDirector/PDMR Shareholding
21st Nov 20173:08 pmRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSTrading Statement
14th Nov 201710:39 amRNSDirector/PDMR Shareholding
16th Oct 20175:35 pmRNSDirector/PDMR Shareholding
29th Sep 20173:36 pmRNSHolding(s) in Company
9th Aug 20177:00 amRNSHalf-year Report
4th Jul 20177:00 amRNSCompletion of Acquisition
23rd Jun 20179:11 amRNSTotal Voting Rights
20th Jun 20173:59 pmRNSHolding(s) in Company
12th Jun 20172:20 pmRNSDirector/PDMR Shareholding
5th Jun 20179:08 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSAcquisition of Chromalox for US$415 million
9th May 20174:30 pmRNSResult of AGM
9th May 20177:00 amRNSTrading Statement
4th May 20174:30 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSCompletion of Acquisition
26th Apr 20178:42 amRNSHolding(s) in Company
25th Apr 20179:10 amRNSHolding(s) in Company
19th Apr 20173:55 pmRNSHolding(s) in Company
18th Apr 20173:58 pmRNSHolding(s) in Company
3rd Apr 20177:30 amRNSAcquisition
24th Mar 20174:44 pmRNSTotal Voting Rights
23rd Mar 20171:45 pmRNSDirector/PDMR Shareholding
17th Mar 20174:04 pmRNSDirector/PDMR Shareholding
9th Mar 20177:00 amRNSFinal Results
30th Nov 20167:00 amRNSAcquisition
22nd Nov 20167:00 amRNSTrading Statement
17th Nov 20164:23 pmRNSDirector/PDMR Shareholding
14th Nov 20168:30 amRNSDr Krishnamurthy Rajagopal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.